An Expanded Access Program for SYN023 in Rabies Treatment
ConditionRabies
Trial statusAvailable
Trial phaseNot listed
Trial typeExpanded Access
Biological sexAll
AgeNot listed
SponsorSynermore Biologics (Suzhou) Co., Ltd.
About this trial
This sponsor-initiated Expanded Access Program provides compassionate-use SYN023, a dual monoclonal antibody cocktail (zamerovimab + mazorelvimab) targeting rabies virus glycoprotein, for US patients with confirmed or suspected life-threatening rabies lacking adequate alternative therapies.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Must be ineligible for or lack access to other investigational or approved therapies
Must have no available alternative curative treatment options
Disqualifiers
None
Trial design
Treatments tested in this trial
Zamerovimab and Mazorelvimab Injection
DrugSYN023 may be administered with rabies treatments according to the local standard of care; local standard of care may include the Milwaukee Protocol if the treating clinician and patient so choose.
Treatment groups
No treatment groups listed
Trial outcomes
This trial has no outcomes listed.Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov